Literature DB >> 15660727

Insulin treatment and cardiovascular disease; friend or foe? A point of view.

M J Muis1, M L Bots, D E Grobbee, R P Stolk.   

Abstract

BACKGROUND: Several observational studies have shown that higher insulin levels are associated with an increased risk of cardiovascular disease. If higher endogenous insulin levels are causally related to cardiovascular disease, one might expect an increased risk of cardiovascular disease in patients treated with insulin, as this results in high circulating insulin levels. Such risk elevation might counteract the benefits of tight glucose control. Our objective was to explore the relationship between insulin therapy and cardiovascular disease in Type 1 and Type 2 diabetes mellitus using information from available literature. SUMMARY OF COMMENT: Several experimental studies in animals and humans support the presence of a harmful effect of insulin on the vascular endothelium. In prospective follow-up studies increased insulin dosage was associated with increased risks of cardiovascular disease, although confounding by indication could not be excluded. Randomized controlled trials in diabetic patients, comparing conventional with intensive glucose-lowering treatment, although showing a reduction in microvascular disease, showed no significant difference in the incidence of cardiovascular disease. The results with respect to exposure to insulin are, however, difficult to interpret due to insufficient information on exposure to insulin levels as well as confounding by glycaemic control and body mass index. In addition, these studies were not designed to address the question whether higher insulin use relates to increased cardiovascular risk.
CONCLUSION: Published research provides conflicting evidence as to whether exposure to high levels of exogenous insulin in diabetes mellitus affects the risk of cardiovascular disease. The currently available studies have a number of serious methodological restraints that limit accurate interpretation and conclusions in this area.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15660727     DOI: 10.1111/j.1464-5491.2004.01416.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  16 in total

Review 1.  Cardiovascular impact of drugs used in the treatment of diabetes.

Authors:  Chris R Triggle; Hong Ding
Journal:  Ther Adv Chronic Dis       Date:  2014-11       Impact factor: 5.091

Review 2.  Effects of chronic hyperinsulinemia in insulin-resistant patients.

Authors:  Sergio Muntoni; Sandro Muntoni; Boris Draznin
Journal:  Curr Diab Rep       Date:  2008-06       Impact factor: 4.810

Review 3.  Type 2 diabetes pharmacoepidemiology update 2014: safety versus efficacy.

Authors:  Sonal Singh
Journal:  Curr Diab Rep       Date:  2014-12       Impact factor: 4.810

4.  Is A1C Variability an Independent Predictor for the Progression of Atherosclerosis in Type 2 Diabetic Patients?

Authors:  Chul Sik Kim; So Young Park; Sung Hoon Yu; Jun Goo Kang; Ohk Hyun Ryu; Seong Jin Lee; Eun Gyung Hong; Hyeon Kyu Kim; Doo-Man Kim; Jae Myung Yoo; Sung Hee Ihm; Moon Gi Choi; Hyung Joon Yoo
Journal:  Korean Diabetes J       Date:  2010-06-30

5.  Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis.

Authors:  G Schernthaner; A H Barnett; D J Betteridge; R Carmena; A Ceriello; B Charbonnel; M Hanefeld; R Lehmann; M T Malecki; R Nesto; V Pirags; A Scheen; J Seufert; A Sjohölm; A Tsatsoulis; R DeFronzo
Journal:  Diabetologia       Date:  2010-03-31       Impact factor: 10.122

6.  Effects of insulin dependence on inflammatory process, thrombotic mechanisms and endothelial function, in patients with type 2 diabetes mellitus and coronary atherosclerosis.

Authors:  Charalambos Antoniades; Dimitris Tousoulis; Kyriakoula Marinou; Nikos Papageorgiou; Erini Bosinakou; Costas Tsioufis; Elli Stefanadi; George Latsios; Costas Tentolouris; Gerasimos Siasos; Christodoulos Stefanadis
Journal:  Clin Cardiol       Date:  2007-06       Impact factor: 2.882

7.  The association between C-reactive protein levels and insulin therapy in obese vs nonobese veterans with type 2 diabetes mellitus.

Authors:  Sameed Ahmed M Khatana; Tracey H Taveira; Andrea G Dooley; Wen-Chih Wu
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-06       Impact factor: 3.738

Review 8.  Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus.

Authors:  Birgit Fullerton; Klaus Jeitler; Mirjam Seitz; Karl Horvath; Andrea Berghold; Andrea Siebenhofer
Journal:  Cochrane Database Syst Rev       Date:  2014-02-14

Review 9.  Combining insulins with oral antidiabetic agents: effect on hyperglycemic control, markers of cardiovascular risk and disease.

Authors:  Kjeld Hermansen; Lene Sundahl Mortensen; Marie-Louise Hermansen
Journal:  Vasc Health Risk Manag       Date:  2008

Review 10.  Comparative cardiovascular morbidity and mortality in patients taking different insulin regimens for type 2 diabetes: a systematic review.

Authors:  Hilary I Price; Meghan D Agnew; John-Michael Gamble
Journal:  BMJ Open       Date:  2015-03-11       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.